ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > HALT !!!

<< Previous

Bullboard Posts

Next >>

Comment by Annayyaon Aug 17, 2021 7:26pm

141 Views

Post# 33721417

RE:RE:RE:RE:RE:RE:HALT !!!

For once could it be possible that they are moving the timelines ahead for a change. I really hope so.

Gbathat wrote: $15M would be enough to cover Pre-clincal development for Ph1 for PMN310. But I thought the latest documents filed by the company indicated that they would not apply for Ph1 consideration until the end of 2022.

from the Aug 12 MD&A
------------------
Should further capital be available on a timely basis, ProMIS estimates it will be able to complete in Q4, 2022, the pre-clinical work necessary to enable ProMIS to submit an IND application to the FDA to approve PMN310 for Phase 1 clinical testing in humans in the U.S. The Company has not yet determined timelines to commence and complete a Phase 1 clinical trial.
-------------------

I gues we are seeing further capital being available on a timely basis. that is good. The timelines and costs are still far off from their investor presentations from last summer, but at least we seem to be tracking a plan now.